ALLMedicine™ Pituitary Tumors Center

Jun 25th, 2022 - In this brief report, we review the unique characteristics of Cushing disease (CD) in children, as well as the most important new genetic discoveries associated with childhood CD. We often forget it, but CD refers to Cushing syndrome caused by pit...

Jun 24th, 2022 - This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors. CRH stimulation and 18F-FDG uptake in PET imaging will be used to detect ...

Jun 24th, 2022 - Study Description: This protocol aims to evaluate subjects with tumors of the hypothalamic pituitary unit to: identify genetic components of pituitary and hypothalamic oncogenesis, to develop new clinical studies for the recognition and thera...

Jun 23rd, 2022 - Although pituitary tumors are among the most common types of brain tumor, the underlying molecular mechanism of this disease remains obscure. To this end, the role of sirtuin 1 (SIRT1) in pituitary tumors was reported. The results of reverse trans...

Jun 17th, 2022 - Background The somatotroph cells of the anterior pituitary gland produce growth hormone (GH), which is stimulated by GH-releasing hormone (GHRH) and inhibited by somatostatin, both of which are produced by the hypothalamus. Adult GH deficiency can...

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Visual symptoms from NFPAs are common and include visual field defects, loss of central vision, and motility problems resulting in diplopia. To create evidence-based...

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. To create evidence-based guidelines for the initial management of NFPAs. A multidisciplinary task force composed of physician volunteers and evidence-based medicine-...

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Due to the lack of hormonal hypersecretion, posttreatment follow-up evaluation of NFPAs is challenging. To create evidence-based guidelines in an attempt to formulat...

Jun 24th, 2022 - This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors. CRH stimulation and 18F-FDG uptake in PET imaging will be used to detect ...

Jun 24th, 2022 - Study Description: This protocol aims to evaluate subjects with tumors of the hypothalamic pituitary unit to: identify genetic components of pituitary and hypothalamic oncogenesis, to develop new clinical studies for the recognition and thera...

May 19th, 2022 - The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.

Apr 20th, 2022 - BACKGROUND AND CLINICAL SIGNIFICANCE Over the past decade, the surgical method for removing pituitary tumors has shifted from a microscopic resection technique performed exclusively by a neurosurgeon, to an endoscopic resection done as a team with...

Mar 31st, 2022 - Background The most common cause to pituitary insufficiency is the pituitary adenoma (PA). PA may be divided into hormone producing PAs and non-functioning PAs (NFPA). Normal pituitary tissue, as well as tissues from PAs, expresses somatostatin re...

Dec 5th, 2019 - The 2019 Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care issued by two key US endocrine societies cover important developments in the decade since the previous version.   The...

Apr 26th, 2018 - CHICAGO – Management of fertility and reproduction for women with prolactin-secreting pituitary tumors is a balancing act, often in the absence of robust data to support clinical decision making. So judgment, communication, and paying attention to.

Apr 19th, 2018 - Guidelines issued jointly by the Endocrine Society and the European Society for Endocrinology provide clinicians with a clear consensus approach to male hypogonadism, commonly referred to by patients as “low T. ” Hypogonadism results from “the fail.

Nov 8th, 2017 - Pituitary Tumors and Carcinomas European Society of Endocrinology Recommend all pituitary tumors undergo histopathologic analysis, which should include, at a minimum, immunodetection of pituitary hormones and Ki-67 proliferative index evaluation. ...

Apr 2nd, 2017 - ORLANDO – Temozolomide, an alkylating agent approved for glioblastoma, improved long-term survival in about half of patients who took it for aggressive pituitary tumors, a retrospective study has determined. The study, conducted by members of the.